STEP® technology increases protein expression in CHO cells with at least 10-fold, taking a mere 14 weeks to generate stable cell clones. STEP® is a novel plasmid based expression platform. By means of a highly stringent selection our platform achieves extreme high protein expression levels in CHO cells without the need for gene amplification or time-consuming rounds of cell sub cloning.
STEP® technology enables the rapid generation of stable, mammalian CHO cell lines, able to provide at least 10-fold more product per cell as compared to benchmark cell lines. In the rapidly growing market of recombinant proteins and antibodies our STEP® technology provides a tool to complete preclinical phases at higher speed, with reduced costs, and with a higher success rate.
STEP® technology is based on three key features. An impaired Zeocin selection marker and DNA spacer that reduce both translation of the Zeocin protein and its functionality. Novel potent expression enhancing elements increase gene expression and allow cells to survive high selection stringency. Linkage of the selection marker to the Gene Of Interest results in one mRNA molecule with high expression of the product in surviving cells.